.@cnsternberg gives us the latest from the PROSPER study, in which PSA response in men with nonmetastatic castration-resistant prostate cancer were treated with enzalutamide https://t.co/dCmmvGzkD9 #EAU18
.@cnsternberg gives us the latest from the PROSPER study, in which PSA response in men with nonmetastatic castration-resistant prostate cancer were treated with enzalutamide https://t.co/dCmmvGzkD9 #EAU18